Home Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia
Article
Licensed
Unlicensed Requires Authentication

Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia

  • Eko Prasetio ORCID logo , Wahyu Utami , Zulhabri Othman , Ari Wardani , Abdul Rahem and Andi Hermansyah ORCID logo EMAIL logo
Published/Copyright: February 7, 2020

Abstract

Background

The Government of Indonesia has put in place many interventions for rationalizing drug use at all levels of the health services including in primary care centers (puskesmas). One of the programs for the rational use of drugs at the puskesmas is the monitoring and evaluation of drug use conducted by pharmacists. The purpose of this research was to evaluate the rationality of drug use in Pamekasan puskesmas that use World Health Organization (WHO) prescribing indicators and to find the difference in the percentage of rationality of drug use between puskesmas in Pamekasan.

Methods

This study reviewed official documents considering reporting of rational drug use. The documents were obtained from the district health office or from the public domain from 2014 to 2018. Data were then collated, extracted, and presented as frequencies.

Results

The percentage prescribed for antibiotics for acute respiratory infection (ARI) non-pneumonia was 47.27% and percentage prescribing antibiotic drugs in a non-specific diarrhea was 59.85%. The percentage prescribed for injection was 36.15%. The average number of drugs prescribed per treatment was 2.61.

Conclusions

The majority of WHO guidelines stated that prescribing indicators were not met by the puskesmas in Pamekasan, except for the parameters for the average number of drugs prescribed per consultation. This shows an alarming clarion call for the local healthcare stakeholders to improve such situations.

Acknowledgments

The authors thank the Pamekasan District Health Office and East Java Province Health Office for supporting data related rational drug use.

  1. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  2. Research funding: None declared.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors' institutional review board or equivalent committee. (070/8324/209.4/2019). This study has obtained permission from the Government of East Java Province and District Health Office Pamekasan, Indonesia.

References

[1] Mekonnen S, Getnet M, Bereket M, Firehiwot A, Tesfaye G. Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study. BMC Health Serv Res 2017;17:161.10.1186/s12913-017-2097-3Search in Google Scholar PubMed PubMed Central

[2] Aqeel A, Sobia K, Maria M, Sidra M, Babar M. Evaluation of Rational Drug Use at Teaching Hospitals in Punjab, Pakistan. J Pharm Pract Commun Med 2016;2:54–7.10.5530/jppcm.2016.2.6Search in Google Scholar

[3] Cindra TY, Kusnandar A, Alfi NI. Evaluation of rational drug use for acute pharyngitis associated with the incidence and prevalence of the disease at two community health centers in Indonesia. Sci Pharm 2017;85:2–9.10.3390/scipharm85020022Search in Google Scholar

[4] World Health Organization. Promoting rational use of medicine: core component. WHO policy perspective on medicine. Geneva: World Health Organization, 2002.Search in Google Scholar

[5] Ministry of Health of the Republic of Indonesia. Module for the use of rational drugs. Jakarta: Ministry of Health of the Republic of Indonesia, 2015.Search in Google Scholar

[6] Ministry of Health of the Republic of Indonesia. Mobilization module using rational medication. Jakarta: Ministry of Health of the Republic of Indonesia, 2012.Search in Google Scholar

[7] Kardela W, Andrajati R, Supardi S. Comparison of rational drug use based on WHO indicators in district health centers between Depok City and South Jakarta. J Kefarmasian Indonesia 2014;4:91–102.Search in Google Scholar

[8] Ministry of Health of the Republic of Indonesia. Decree of the minister of health of the Republic of Indonesia number 128/MENKES/SK/II/2004 about the basic policy of the public health center. Jakarta: Ministry of Health of the Republic of Indonesia, 2004.Search in Google Scholar

[9] Pamekasan Health Office. Pamekasan regency health profile 2018. Pamekasan Health Office, 2019.Search in Google Scholar

[10] Destiani D, Naja S, Nurhadiyah A, et al. Outpatient prescribing patterns: observational studies using WHO prescribing criteria in one of the Bandung health facilities. J Farmasi Klinik Indonesia 2016;5:225–31.10.15416/ijcp.2016.5.3.225Search in Google Scholar

[11] Sukandar EY, Andrajati R, Sigit JI, Adnyana IK, Setiadji AA, Kusnandar. Iso Farmakoterapi. Jakarta: PT. ISFI, 2008.Search in Google Scholar

[12] Senok AC, Ismaeel AY, Al-Qashar FA, Agab WA. Pattern of upper respiratory tract infections and physicians’ antibiotic prescribing practices in Bahrain. Med Princ Pract 2009;18:170–4.10.1159/000204345Search in Google Scholar PubMed

[13] Pathak D, Pathak A, Marrone G, Diwan V, Lundborg CS. Adherence to treatment guidelines for acute diarrhoea in children up to 12 years in Ujjain, India – a cross sectional prescription analysis. BMC Infect Dis 2011;11:32.10.1186/1471-2334-11-32Search in Google Scholar PubMed PubMed Central

[14] Sadikin ZD. Rational drug use. J Indon Med Assoc. 2011;61:4.Search in Google Scholar

[15] Hermansyah A, Sukorini AI, Setiawan CD, Priyandani Y. The conflicts between professional and non professional work of community pharmacists in Indonesia. Pharm Pract (Internet). 2012;10:33–9.10.4321/S1886-36552012000100006Search in Google Scholar PubMed PubMed Central

[16] Hermansyah A, Sainsbury E, Krass I. Multiple policy approches in improving community pharmacy practice: the case in Indonesia. BMC Health Serv Res 2018;18:449.10.1186/s12913-018-3258-8Search in Google Scholar PubMed PubMed Central

Received: 2019-10-31
Accepted: 2019-11-15
Published Online: 2020-02-07

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Reviews
  2. Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review
  3. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review
  4. Original Articles
  5. Quercetin attenuates acute predator stress exposure-evoked innate fear and behavioral perturbation
  6. Evaluating current practices and policies in the use of injectable medicines for treating myalgia in a primary care center in Pamekasan, Indonesia
  7. The contemporary role and potential of pharmacist contribution for community health using social media
  8. Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia
  9. The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting
  10. Factors affecting community pharmacist’s service for women with chronic diseases during pregnancy and breastfeeding: application of the Health Belief Model
  11. Overview of therapeutic changes in antiepileptic drugs in adult patients
  12. Exploration of barriers affecting job satisfaction among community pharmacists
  13. Patients’ characteristics and their adherence to insulin therapy
  14. Correlation of chemotherapy costs with quality of life in nasopharyngeal cancer patients
  15. Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia
  16. Translation, cultural adaptation, and validation of the quality of well being self-administered questionnaire in general population in Indonesia
  17. Knowledge, attitude, and practice of pharmacists towards management of hypertension in primary care centers
  18. Medication adherence in diabetes mellitus patients at Tanjung Karang Primary Health Care Center, Mataram
  19. Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2
  20. Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole
  21. The effect of curcuma (Curcuma xanthorrizha roxb.) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (Mus musculus) with hypertension
  22. Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model
  23. Medical problems in patients with chronic kidney disease undergoing hemodialysis and their therapy
  24. ADMET properties of novel 5-O-benzoylpinostrobin derivatives
  25. Development of nonalcoholic fatty liver disease model by high-fat diet in rats
  26. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor
  27. The relationship between the level of education and accuracy of insulin injection techniques in DM patients with measurement of HbA1c values
  28. The effect of premixed insulin to blood glucose concentration in patients with type 2 diabetes mellitus
  29. Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness
  30. Adherence behavior assessment of oral antidiabetic medication use: a study of patient decisions in long-term disease management in primary health care centers in Surabaya
  31. Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma
  32. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients
  33. Antineuroinflammation activity of n-butanol fraction of Marsilea crenata Presl. in microglia HMC3 cell line
  34. The enhancement of Arg1 and activated ERβ expression in microglia HMC3 by induction of 96% ethanol extract of Marsilea crenata Presl. leaves
  35. Ternary solid dispersion to improve solubility and dissolution of meloxicam
  36. Improving solubility and dissolution of meloxicam by solid dispersion using hydroxypropyl methylcellulose 2910 3 cps and nicotinamide
  37. o-Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y12 receptors
  38. The change of proinflammatory cytokine tumor necrosis factor α level in the use of meloxicam in rat model of osteoarthritis
  39. Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis
  40. Analysis of effectiveness and drug related problems of pain reliever for knee osteoarthritis: weighing clinical risk and benefit
  41. Comparison of antibiotic prescriptions in adults and children with upper respiratory tract infections in Bangka Tengah primary health care centers
  42. Profile of sociodemographics, sources of infection, antiretrovirals and CD4 counts on HIV/AIDS outpatients in Turen Primary Health Centre, Indonesia
  43. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor
  44. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method
  45. Knowledge and attitude: two fundamental factors that determine patient compliance in antibiotic therapy
  46. Molecular docking study of sappan wood extract to inhibit PBP2A enzyme on methicillin-resistant Staphylococcus aureus (MRSA)
  47. Effect of curcumin analogue synthetic product from cullilawan oil for the liver damage treatment in male mice (Mus musculus L.)
  48. Case Report
  49. A case report of generalized tetanus in a 42-year-old man with dental infection
Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2019-0326/html
Scroll to top button